The fight against advanced cancer just got a significant boost, as ONA Therapeutics announced it has secured $86.6M in Series B funding. The biotech firm is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer, aiming to provide effective new treatments for patients with no remaining alternatives.
This latest capital infusion saw participation from a syndicate of investors including Columbus Venture Partners, Merieux Equity Partners, Korys, COFIDES, and Bpifrance, among others. ONA Therapeutics focuses on discovering novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients, combining privileged biology with its expertise in biologics to craft ADCs and antibody therapies.















